Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Wedbush analyst David Nierengarten maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $40.00. The company’s shares closed yesterday at $16.08.

Below is a chart showing NPO's trailing twelve month trading history, with the $180 strike highlighted in orange: And AnaptysBio Inc (Symbol: ANAB) options are showing a volume of 8,724 contracts ...

Shares of ANAB stock opened at $16.06 on Tuesday. The firm has a market cap of $488.71 million and a P/E ratio of -2.64. The firm’s 50 day moving average price is $17.05 and its 200-day moving ...

A live webcast of the call will be avai AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders should be happy to see the share price up 13% in the last month. But that... SAN DIEGO, Feb. 03, 2025 (GLOBE ...

Shares of ANAB stock opened at $21.22 on Thursday. AnaptysBio has a 1 year low of $12.21 and a 1 year high of $41.31. The stock’s 50 day simple moving average is $15.75 and its two-hundred day ...

Mathias Azonnoudo, a 50-year-old farmer in Benin, was taking a break sitting on a large pile of freshly picked cotton, which the government hopes will feed the country's nascent textile revolution.

The Senate voted to confirm Tulsi Gabbard as director of national intelligence on Wednesday, elevating a former lawmaker with controversial foreign policy views to the head of the country’s spy ...